Abdullah M S Al-Hatmi1, Anne D van Diepeningen2, Ilse Curfs-Breuker3, G Sybren de Hoog4, Jacques F Meis5. 1. CBS-KNAW Fungal Biodiversity Centre, PO Box 85167, 3508 AD Utrecht, The Netherlands Institute of Biodiversity and Ecosystem Dynamics, University of Amsterdam, Amsterdam, The Netherlands Directorate General of Health Services, Ibri Hospital, Ministry of Health, Muscat, Oman a.alhatmi@cbs.knaw.nl. 2. CBS-KNAW Fungal Biodiversity Centre, PO Box 85167, 3508 AD Utrecht, The Netherlands. 3. Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands. 4. CBS-KNAW Fungal Biodiversity Centre, PO Box 85167, 3508 AD Utrecht, The Netherlands Institute of Biodiversity and Ecosystem Dynamics, University of Amsterdam, Amsterdam, The Netherlands Peking University Health Science Center, Research Center for Medical Mycology, Beijing, China Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China Shanghai Institute of Medical Mycology, Changzheng Hospital, Second Military Medical University, Shanghai, China Basic Pathology Department, Federal University of Paraná State, Curitiba, Paraná, Brazil King Abdulaziz University, Jeddah, Saudi Arabia. 5. Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands Department of Medical Microbiology, Radboud University Medical Centre, Nijmegen, The Netherlands.
Abstract
OBJECTIVES: The aim of the present study was to evaluate and assess the in vitro activity of eight drugs, including the new azole isavuconazole, against 81 strains representing 13 species of the Fusarium fujikuroi species complex. METHODS: A total of 81 Fusarium spp. isolates, within the F. fujikuroi species complex, were identified by molecular methods and tested according to CLSI M38-A2. Eight antifungal compounds, including the new azole isavuconazole, were tested. Isolates were selected to represent the widest variety of geographical regions and to include clinical as well as environmental strains. RESULTS: Susceptibility profiles differed between and within species, with Fusarium verticillioides showing the lowest MICs and Fusarium nygamai the highest MICs. Amphotericin B was the most active drug, followed by voriconazole, posaconazole, isavuconazole and natamycin. The remaining antifungals (fluconazole, itraconazole and micafungin) showed poor activity with MIC/minimum effective concentration values of ≥ 32, ≥ 16 and >8 mg/L, respectively. CONCLUSIONS: Resistance patterns in the F. fujikuroi species complex are species specific and therefore identification down to species level is important for the choice of antifungal treatment.
OBJECTIVES: The aim of the present study was to evaluate and assess the in vitro activity of eight drugs, including the new azole isavuconazole, against 81 strains representing 13 species of the Fusarium fujikuroi species complex. METHODS: A total of 81 Fusarium spp. isolates, within the F. fujikuroi species complex, were identified by molecular methods and tested according to CLSI M38-A2. Eight antifungal compounds, including the new azole isavuconazole, were tested. Isolates were selected to represent the widest variety of geographical regions and to include clinical as well as environmental strains. RESULTS: Susceptibility profiles differed between and within species, with Fusarium verticillioides showing the lowest MICs and Fusarium nygamai the highest MICs. Amphotericin B was the most active drug, followed by voriconazole, posaconazole, isavuconazole and natamycin. The remaining antifungals (fluconazole, itraconazole and micafungin) showed poor activity with MIC/minimum effective concentration values of ≥ 32, ≥ 16 and >8 mg/L, respectively. CONCLUSIONS: Resistance patterns in the F. fujikuroi species complex are species specific and therefore identification down to species level is important for the choice of antifungal treatment.
Authors: B Dalyan Cilo; A M S Al-Hatmi; S Seyedmousavi; A J M M Rijs; P E Verweij; B Ener; G S de Hoog; A D van Diepeningen Journal: Eur J Clin Microbiol Infect Dis Date: 2015-05-21 Impact factor: 3.267
Authors: Ana Alastruey-Izquierdo; Laura Alcazar-Fuoli; Olga Rivero-Menéndez; Josefina Ayats; Carmen Castro; Julio García-Rodríguez; Lidia Goterris-Bonet; Elisa Ibáñez-Martínez; María José Linares-Sicilia; M Teresa Martin-Gomez; Estrella Martín-Mazuelos; Teresa Pelaez; Javier Peman; Antonio Rezusta; Susana Rojo; Rocio Tejero; Diego Vicente Anza; Jesús Viñuelas; Maria Soledad Zapico; Manuel Cuenca-Estrella Journal: Antimicrob Agents Chemother Date: 2018-08-27 Impact factor: 5.191
Authors: Mahdi Abastabar; Abdullah M S Al-Hatmi; Mohammad Vafaei Moghaddam; G Sybren de Hoog; Iman Haghani; Seyed Reza Aghili; Tahereh Shokohi; Mohammad Taghi Hedayati; Roshanak Daie Ghazvini; Reza Kachuei; Ali Rezaei-Matehkolaei; Koichi Makimura; Jacques F Meis; Hamid Badali Journal: Antimicrob Agents Chemother Date: 2018-04-26 Impact factor: 5.191
Authors: Abdullah M S Al-Hatmi; Anne-Cécile Normand; Stephane Ranque; Renaud Piarroux; G Sybren de Hoog; Joseph Meletiadis; Jacques F Meis Journal: Antimicrob Agents Chemother Date: 2016-12-27 Impact factor: 5.191
Authors: Chhavi Gupta; Marit Jongman; Shukla Das; K Snehaa; S N Bhattacharya; S Seyedmousavi; Anne D van Diepeningen Journal: Mycopathologia Date: 2016-05-02 Impact factor: 2.574
Authors: Marcela Guevara-Suarez; José Francisco Cano-Lira; María Caridad Cepero de García; Leticia Sopo; Catalina De Bedout; Luz Elena Cano; Ana María García; Adriana Motta; Adolfo Amézquita; Martha Cárdenas; Ana Espinel-Ingroff; Josep Guarro; Silvia Restrepo; Adriana Celis Journal: Mycopathologia Date: 2016-03-04 Impact factor: 2.574